Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

Introduction Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the first-line treatment of ALK-positive metastatic non-small cell lung cancer, frequently associated with psychiatric adverse events. Method This study presents the clinical case of a patient who was successfully treated with low-dose trazodone for lorlatinib-induced psychiatric symptoms. In addition, an overview of the existing literature on the management of psychiatric adverse events (AEs) associated with ALK inhibitors is provided. Results and conclusions Based on the evidence presented and the preliminary outcomes observed in the reported case, this study aims to outline a management strategy for lorlatinib-related psychiatric complications.